Role of tumour markers in monitoring epithelial ovarian cancer

Meyer T, T Meyer, G J Rustin, Rustin GJ
British journal of cancer · 2000 · vol. 82(9) , pp. 1535–8 · doi:10.1054/bjoc.2000.1174 · PMID:10789720 · PMC2363391
Review OA: gold CC-BY-4.0
📄 Open PDF View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-25 ⓘ

This review identifies CA125 as the only validated tumor marker for monitoring epithelial ovarian cancer response and progression, while noting its limited diagnostic utility and the experimental status of other markers.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Currently the only tumour marker to have a well-defined and validated role in the management of ovarian cancer is CA125. Changes in the level of CA125 can be used as a reliable indication of response or progression according to various criteria, but it does not yet have a clear place in diagnosis or prognosis. Its value as part of a screening tool and during routine follow-up remain the subject of ongoing trials. Other markers remain experimental and do not have a well-defined contribution to make at present.

My notes (saved in your browser only)

MeSH descriptors

Biomarkers, Tumor CA-125 Antigen Ovarian Neoplasms Biomarkers, Tumor CA-125 Antigen Female Humans Monitoring, Physiologic Ovarian Neoplasms Ovarian Neoplasms Ovarian Neoplasms Recurrence

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-18T09:30:06.152893+00:00
pubmed
last seen: 2026-10-08T20:59:21.759586+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC